<DOC>
	<DOCNO>NCT02214004</DOCNO>
	<brief_summary>The purpose study evaluate whether trastuzumab letrozole effective safe preoperative treatment postmenopausal patient hormone receptor-positive HER2-positive breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Trastuzumab Letrozole Postmenopausal Women</brief_title>
	<detailed_description>Eligibility criterion - Ages Eligible Study : ≥ 20 year - Invasive cancer ( clinical stage IB-IIIB ) - Measurable tumor large 1cm - ECOG status 0 1 - Postmenopausal woman - Age ≥55 year amenorrhea - Age &lt; 55 year amenorrhea ≥12 month FSH &gt; 30 mIU/ml - HER2 positive tumor - 3 positive IHC - 2 positive IHC HER2 gene amplification FISH SISH use single-probe dual-probe - Estrogen receptor positive tumor - Positive ER expression Allred score PS3/TS8 modify Allred score PS4/TS7 - Eligible cardiac function - Normal heard evaluate ECG - Consider clinically non-significant arrythmia ischemic change normal - LVEF ≥ 55 % measure ECHO MUGA scan Outcome measure - Primary End-point - The rate pathologic complete response ( pCR ) - No residual invasive cancer breast - Secondary End-point - Clinical Response Rate - Safety profile preoperative use concurrent trastuzumab letrozole - The rate breast conservative surgery - Total pathologic complete response ( tpCR ) - No residual invasive cancer breast ipsilateral axilla - Analysis biomarkers base baseline specimen residual tumor - Ki67 expression - cDNA microarray : gene expression profile - Association clinical response rate circulate tumor cell ( CTCs ) - CTCs measure CytoGen ( SEOUL , KOREA ) ''</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Invasive cancer ( clinical stage IBIIIC ) Measurable tumor large 1cm ECOG status 0 1 Postmenopausal woman Age ≥55 year amenorrhea Age &lt; 55 year amenorrhea ≥12 month FSH &gt; 30 mIU/ml HER2 positive tumor 3 positive IHC 2 positive IHC HER2 gene amplification FISH SISH use singleprobe dualprobe Estrogen receptor positive tumor Positive ER expression Allred score PS3/TS8 modify Allred score PS4/TS7 Eligible cardiac function Normal heard evaluate ECG Consider clinically nonsignificant arrythmia ischemic change normal LVEF ≥ 55 % measure ECHO MUGA scan Inflammatory breast cancer Bilateral breast cancer Patients previous breast cancer history Patients previous breast cancer treatment : Generally include hormone therapy , chemotherapy , radiotherapy ) Patients uncontrolled heart problem Ischemic heart disease within 6 month Congestive heart failure NYHA class II Unstable angina Clinically significant pericarditis Amyloid heart disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>HER2</keyword>
	<keyword>ER</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Neoadjuvant endocrine treatment</keyword>
</DOC>